When radiotherapy was added to androgen deprivation therapy, only minimal impact on health-related quality-of-life in prostate cancer
Adding bevacizumab to standard treatment of glioblastoma may have no impact on health-related quality of life.
Talimogene laherparepvec (T-VEC) is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma.
Addition of bevacizumab to carboplatin/paclitaxel well tolerated in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC).
Many patients with cancer are interested in comprehensive tumor genetic profiling (CGP), and most are willing to pay out-of-pocket costs for CGP.
Vismodegib is safe and effective in the management of advanced basal cell carcinoma (BCC).
Second-line dovitinib in FGFR2-mutated and FGFR2-non-mutated advanced or metastatic endometrial cancer had single-agent activity.
Association between extreme chromosomal instability and improved outcome in estrogen receptor (ER)-negative breast cancers.
A majority of people with a family history of colorectal cancer (CRC) are not getting screened for the disease early enough.
Azacitadine may be an important treatment option for older patients with newly diagnosed acute myeloid leukemia (AML).
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy.
There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients.
A positive family history is not a significant independent risk factor for breast cancer outcome.
Undergoing chemotherapy before surgery may help women battling advanced ovarian cancer.
The prognostic role of tumor infiltrating lymphocytes (TIL) has been confirmed in triple negative early breast cancer.
Gene-expression classifier may improve the diagnostic performance of bronchoscopy in detecting lung cancer.
Bortezomib, cyclophosphamide, and dexamethasone (VCD) is preferable as induction therapy for newly diagnosed multiple myeloma.
For breast and colorectal cancer survivors, level of exercise participation significantly increased with oncologist recommendations.
Not all women with high breast density have high risk of interval cancer.
Stereotactic ablative radiotherapy could be an option for treating patients with operable stage I non-small cell lung cancer (NSCLC).
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
- CD151—A Striking Marker for Cancer Therapy
- Multigene Cancer-Susceptibility Tests Require New Approaches to Patient Counseling
- Addition of Levetiracetam May Improve Survival for Glioblastoma
- Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer
- Vitamin D Levels and Risk for Pancreatic Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Identifying Genetic Variations Associated with Risk of Prostate Cancer
- Adding Radiotherapy to ADT Only Slightly Impacts Quality of Life in Prostate Cancer
- Adding Bevacizumab Has No Impact on Quality of Life in Glioblastoma
- First Oncolytic Immunotherapy Improves Durable Response Rate in Melanoma
- Adding Bevacizumab Effective in Chinese Patients with Nonsquamous Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|